GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akouos Inc (NAS:AKUS) » Definitions » Return-on-Tangible-Equity

Akouos (Akouos) Return-on-Tangible-Equity : -41.90% (As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Akouos Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Akouos's annualized net income for the quarter that ended in Sep. 2022 was $-79.36 Mil. Akouos's average shareholder tangible equity for the quarter that ended in Sep. 2022 was $189.39 Mil. Therefore, Akouos's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2022 was -41.90%.

The historical rank and industry rank for Akouos's Return-on-Tangible-Equity or its related term are showing as below:

AKUS' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -42.96   Med: -33.42   Max: -31.85
Current: -42.96

During the past 4 years, Akouos's highest Return-on-Tangible-Equity was -31.85%. The lowest was -42.96%. And the median was -33.42%.

AKUS's Return-on-Tangible-Equity is not ranked
in the Biotechnology industry.
Industry Median: -48.13 vs AKUS: -42.96

Akouos Return-on-Tangible-Equity Historical Data

The historical data trend for Akouos's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akouos Return-on-Tangible-Equity Chart

Akouos Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Return-on-Tangible-Equity
- - -34.99 -31.85

Akouos Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.40 -40.73 -48.77 -40.95 -41.90

Competitive Comparison of Akouos's Return-on-Tangible-Equity

For the Biotechnology subindustry, Akouos's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akouos's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akouos's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Akouos's Return-on-Tangible-Equity falls into.



Akouos Return-on-Tangible-Equity Calculation

Akouos's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2021 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=-86.671/( (310.614+233.65 )/ 2 )
=-86.671/272.132
=-31.85 %

Akouos's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2022 )  (Q: Jun. 2022 )(Q: Sep. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2022 )  (Q: Jun. 2022 )(Q: Sep. 2022 )
=-79.356/( (197.95+180.838)/ 2 )
=-79.356/189.394
=-41.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2022) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Akouos  (NAS:AKUS) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Akouos Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Akouos's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Akouos (Akouos) Business Description

Industry
Traded in Other Exchanges
N/A
Address
645 Summer Street, Suite 200, Boston, MA, USA, 02210
Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.
Executives
Kearny Acquisition Corp 10 percent owner LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Eli & Co 10 percent owner LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Jennifer Anne Wellman officer: Chief Operating Officer C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
Sachiyo Minegishi officer: Chief Financial Officer C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
5am Ventures V, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Maha Katabi 10 percent owner SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Pivotal Bioventure Partners Fund I G.p., L.p. 10 percent owner 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Heather Preston director, 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102

Akouos (Akouos) Headlines

From GuruFocus